CNSP News and Press, CNS Pharmaceuticals Inc. From 05/25/21

Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (“GBM”) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once th...

The following slide deck was published by CNS Pharmaceuticals, Inc. in conjunction with this event. For further details see: CNS Pharmaceuticals (CNSP) Investor Presentation - Slideshow

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has begun open enrollment for its upcoming study focused on analyzing the efficacy and safety of B...

CNS Pharmaceuticals (CNSP) announces open enrollment for its potentially pivotal study evaluating the efficacy and safety of berubicin in the treatment of recurrent glioblastoma multiforme ((GBM)), an aggressive and incurable form of brain cancer.The company intends to enroll about ...

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis ...

Like many other types of cancer, leukemia currently has no cure. Although treatments are largely dependent on whether the cancer is slow growing or aggressive, most of the treatments are pretty toxic and, in extreme cases, can even cost the patients their lives . There are several types of ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided a clinical update and business outlook and released its financial results for the q...

CNS Pharmaceuticals (CNSP): Q1 Net Loss of $3.6MCash and cash equivalents of $11M."The FDA has granted CNS Pharmaceuticals Orphan Drug Designation for Berubicin, which provides seven years of marketing exclusivity upon approval of an NDA.....In addition to the Company's global trial, sublicen...

CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook Company poised to transition to late-stage clinical company with launch of potentially pivotal study evaluating efficacy of Berubicin in the treatment of adult Glioblastoma Multiforme ...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that its CEO John Climaco will present at the Q2 Virtual Investor Summit at 12...